Difference between CBD and CBDA

CBD and CBDA are both cannabinoids, unique compounds created in hemp and cannabis plants. CBD was widely regarded as the most promising cannabinoid for medical purposes, and as such, CBDA was left out. However, a trend towards the extraction of juice from raw cannabis leaves has brought CBDA back into the limelight, and many people wonder what the difference between the two is.

It is essential to establish from the outset that CBDA and CBD are not psychotropic, they will not cause user euphoria and will not compromise their thinking processes. Although CBDA is primarily considered inactive and therefore associated with CBD, it can have compelling potential. Like CBD and other cannabinoids, CBDA is thought to have antiproliferative and anti-inflammatory traits, among others. However, the abundance of research that is accumulating in favour of CBD has not yet spread in the area of CBDA. CBD's anti-inflammatory, antispasmodic, anti-prolifetic, antiproliferative, antioxidant and other functions make it a versatile cannabinoid that is gaining popularity in many health and wellness industries. So what is CBDA based on?

Nausea and vomiting

Although often labeled as "pharmacologically inactive," CBDA has shown powerful effects against nausea and vomiting in a laboratory environment. A 2013 study of animal models explored not only CBDA's ability to reduce these symptoms, but also its potential to improve 5-HT1A receptor activation.

The results were encouraging; the researchers noted that "compared to cannabidiol, CBDA is much more effective in preventing vomiting in shrews and nausea in rats." In addition, they concluded that CBDA was more effective in improving activation of 5-HT1A receptors, as well as in possibly treating anticipatory nausea.


The anti-inflammatory benefits of CBD are well documented and represent a large part of quality research studies on cannabinoids. CBDA can also be a good candidate to reduce inflammation. In fact, CBDA has been shown to be even more effective than THC in blocking COX-2, an enzyme produced as a result of inflammation. In addition, CBDA 'carboxolic acid grouping' (the "A") was found to be crucial in the role of cannabinoid as a selective COX-2 inhibitor.

Breast Cancer

With regard to breast cancer and CBDA, research in this area is quite poor, and it is contested. For example, Dr. Sean McAllister, a prolific scientist in the field of cannabinoid research, has discovered that THC and CBD appear to inhibit and kill cancer cells. He also found that "compared to CBD, CBDA has had negligible effects in cell viability trials against multiple cancers. So we've never been very interested in this molecule."

This finding is supported by a study by Dr. McAllister entitled "Antitumor activity of plant cannabinoids, with an emphasis on the effect of cannabidiol on human breast carcinoma." The study found that of all cannabinoids (including TH
C, CBG and CBC), CBD was the most powerful in the fight against breast cancer, while CBDA was the least powerful.

On the other hand, a 2012 study based at Hokuriku University found that CBDA prevents the migration of breast cancer cells to an aggressive form of this cancer. But the conclusions drawn from this research are far from concrete.

It is clear that, despite all the gaps in research, cbDA has distinct qualities from CBD that make it a compelling subject. Nevertheless, the two cannabinoids have a relationship that requires more exploration and experimentation. As new cannabinoids are discovered, it is crucial to distinguish the individual characteristics of each of them, as well as how they all interact as complete chemical phyto-complex.

Leave a comment

Votez pour nous sur Top-CBD.eu